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Abstract
Currently marketed vaccines against hepatitis B virus (HBV) based on the small (S) hepatitis B surface antigen (HBsAg) fail to
induce a protective immune response in about 10% of vaccinees. DNA vaccination and the inclusion of PreS1 and PreS2
domains of HBsAg have been reported to represent feasible strategies to improve the efficacy of HBV vaccines. Here, we
evaluated the immunogenicity of SAINT-18-formulated MIDGE-Th1 vectors encoding the S or the large (L) protein of HBsAg
in mice and pigs. In both animal models, vectors encoding the secretion-competent S protein induced stronger humoral
responses than vectors encoding the L protein, which was shown to be retained mainly intracellularly despite the presence
of a heterologous secretion signal. In pigs, SAINT-18-formulated MIDGE-Th1 vectors encoding the S protein elicited an
immune response of the same magnitude as the licensed protein vaccine Engerix-B, with S protein-specific antibody levels
significantly higher than those considered protective in humans, and lasting for at least six months after the third
immunization. Thus, our results provide not only the proof of concept for the SAINT-18-formulated MIDGE-Th1 vector
approach but also confirm that with a cationic-lipid formulation, a DNA vaccine at a relatively low dose can elicit an immune
response similar to a human dose of an aluminum hydroxide-adjuvanted protein vaccine in large animals.
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Introduction
Hepatitis B is a potentially life-threatening liver disease caused
by the hepatitis B virus (HBV). It is a major global health concern
as an estimated 2 billion people have been infected with the virus.
About 360 million people live with chronic HBV infections which
can later develop into liver cirrhosis or liver cancer and about
600,000 people die every year from HBV-related disease [1]. HBV
contains three envelope proteins encoded within a single open
reading frame. Depending on the translation initiation sites, three
proteins are produced: (1) the small (S) protein as the major
constituent of the HBV envelope and secreted surface antigen
(HBsAg) particles, (2) the middle (M) protein containing the PreS2
domain at the N-terminus of the S protein, and (3) the large (L)
protein containing a further addition of the PreS1 domain at the
N-terminus of the M protein [2]. In natural infection with HBV,
the envelope proteins can be secreted as subviral HBsAg particles
that contain high amounts of S protein, variable amounts of M
protein and traces of L protein embedded in host cell-derived
lipids [3].
Recombinant expression of the S protein in yeast yields HBsAg
particles which are the basis of currently marketed vaccines against
HBV [4]. A three-dose series of these vaccines administered over a
period of 6 months is recommended for protection against
infection, which is considered to be correlated to S protein-
specific (anti-HBs) antibody levels. Though conventional vaccines
induce protective antibody responses in .90% of healthy adult
recipients, they fail in non-responders like elderly, smokers,
chronically ill or immuno-compromised vaccinees [5]. Thus,
improved vaccines are still desirable.
Research and development of next generation vaccines against
HBV comprise the use of novel adjuvants for recombinant HBsAg
[4,6,7,8], DNA vaccines [9,10] as well as additional or optimized
antigens [11,12,13]. The so-called third-generation vaccines
contain PreS1 and PreS2 domains of HBsAg that harbor a
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number of epitopes relevant for attachment and uptake of HBV
into hepatocytes. Neutralizing antibodies against these epitopes
extend the protective capacity of a vaccine [14,15]. Consequently,
third-generation vaccines exhibited enhanced immunogenicity
also in non-responders to conventional vaccines [11,12,13].
However, due to the necessary glycosylation of PreS1 and PreS2
domains, they must be produced in mammalian cell cultures.
Thus, extra costs for manufacturing in comparison to yeast-
derived vaccines have impeded marketing and introduction into
clinical practice. Here, the use of DNA vaccine technology holds
inherent benefits.
We have previously developed DNA vectors with reduced size,
the Minimalistic Immunogenically Defined Gene Expression
(MIDGE) vectors [16]. MIDGE-Th1 vectors are linear double-
stranded DNA molecules, which are closed with single-stranded
hairpin loops at both ends and contain a peptide nuclear
localization sequence covalently bound to one of the loops. They
exclusively comprise the expression cassette. Immunization with
MIDGE-Th1 vectors elicits strong humoral and cellular immune
responses [17,18]. When formulated with the cationic lipid
SAINT-18 [19], MIDGE-Th1 DNA vaccines induce significantly
increased antibody responses against the S protein of HBsAg in
mice [20].
In our work presented here, we aimed to develop a novel,
effective, SAINT-18-formulated DNA vaccine against HBV. To
this end, we constructed MIDGE-Th1 vectors encoding either the
S or the L protein of HBsAg and characterized their expression
pattern in vitro and evaluated their immunogenicity in mice. To
demonstrate prophylactic efficacy in a large animal model, we
compared our SAINT-18-formulated MIDGE-Th1 vector ap-
proach to the protein vaccine Engerix-B in pigs.
Materials and Methods
Ethics statement
The animal studies were carried out in strict accordance with
German animal welfare regulations and Good Laboratory Practice
(GLP) regulations at LPT (Laboratory of Pharmacology and
Toxicology, Hamburg, Germany) with prior approval of LPT’s
institutional animal care and use commissary (mouse study: 27619;
pig study: 28295) and of the relevant authorities (mouse study:
Beho¨rde fu¨r Gesundheit und Verbraucherschutz, V 11307-591-
00.33; pig study: Ministerium fu¨r Landwirtschaft, Umwelt und
la¨ndliche Ra¨ume, V 312-72241.123-1).
Construction and synthesis of MIDGE-Th1 vectors
The coding sequence of the L protein of HBsAg containing the
PreS1, PreS2 and S coding sequences (subtype adw2, GenBank:
AM282986.1 [21]) was optimized for human codon usage and
synthesized by GeneArt (Regensburg, Germany). The first 7
amino acids of the LHBsAg coding sequence were replaced by the
signal sequence of b-lactamase from plasmid pBluescript KS(+)
(Stratagene, Santa Clara, USA) (59-ATGAGTATTCAA-
CATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCAT
TTTGCCTTCCTGTTTTTGCTCACCCA-
GAAACGCTGGTGAAGTAAAA) as previously described [22]
to yield the antigen coding sequence for the L protein expression
vector (Figure 1). The same S coding sequence as in the L protein
expression vector was used as antigen coding sequence to construct
the S protein expression vector (Figure 1). The synthesis of
MIDGE-Th1 vectors has been described previously [17]. Briefly,
the antigen coding sequences were inserted into plasmids
containing Eco31I recognition sites flanking the expression
cassette, which consists of the CMV immediate-early enhancer/
promoter, a chimeric intron composed of the 59-donor site from
the first intron of the human b-globin gene, the branch point, and
39-acceptor site from the intron of an immunoglobulin gene heavy
chain variable region and a SV40 polyadenylation signal. The
expression cassette was released by Eco31I (Thermo Scientific,
Vilnius, Lithuania) digestion of the plasmids. Subsequently, each
end of the cassette was protected against exonuclease digestion by
ligating a specific hairpin oligodeoxyribonucleotide (ODN) with
one of them crosslinked to a NLS peptide (PKKKRKVEDPYC).
Unprotected DNA fragments were digested using the exonuclease
activity of T7 DNA Polymerase (Thermo Scientific) and the
MIDGE-Th1 products (MIDGE-S-Th1:1,881 bp; MIDGE-L-
Th1:2,458 bp) were purified by anion exchange chromatography
(Fractogel EMD DMAE, Merck KGaA, Darmstadt, Germany)
and concentrated by precipitation with 96% (v/v) ethanol.
In vitro expression of HBsAg
The expression of the S and L proteins from DNA vectors was
examined in CHO-K1 cells (ATCC CCL-61). Cells were grown in
Ham’s F-12 medium supplemented with 10% (v/v) inactivated
fetal bovine serum (FBS) and 100 U/ml penicillin and 100 mg/ml
streptomycin at 37uC in 5% CO2. Prior to transfection, cells were
detached by trypsin and suspended in Ham’s F-12 without FBS
and antibiotics. Then, 2–36106 cells were transfected with 20 mg
DNA (if not indicated otherwise) by electroporation (single pulse,
270 V and 1,650 mF). As control, cells were transfected with
eGFP-encoding vector.
24 h after transfection, cells were lysed by nitrogen decompres-
sion (Cell Disruption Vessel 4639, Parr Instruments, Moline,
USA). Lysates were centrifuged at 1,0006g for 1 min to sediment
the nuclei. Supernatants were centrifuged at 14,0006g for 30 min
to sediment the membrane-containing fraction. The pellet was
suspended in 60 ml of Hepes buffer (20 mM Hepes pH 8.0, 1 mM
DTT, 1 mM EDTA pH 7.6) supplemented with protease
inhibitors. The total protein amount was determined via Bradford
assay. Protein (10 mg) was mixed with Laemmli buffer, then
subjected to SDS-PAGE (12% (w/v) SDS-polyacrylamide gel) and
blotted onto nitrocellulose membrane (Optitran BA-S85, What-
man, Piscataway, USA). Blocking was performed with Roti-Block
(Roth, Karlsruhe, Germany). For detection of the S protein of
HBsAg, S protein-specific horse serum (ab9193, Abcam, Cam-
bridge, UK) at 1:1,000 dilution and HRP-conjugated rabbit anti-
horse IgG (ab6921, Abcam) at 1:20,000 dilution were used. For
detection of the PreS1 domain, PreS1-specific mouse serum
(Proteogenix, Oberhausbergen, France) at 1:1,000 dilution and
HRP-conjugated goat anti-mouse IgG (A9917, Sigma-Aldrich, St.
Louis, USA) at 1:20,000 dilution were used. HRP activity was
detected with SuperSignal West DURA Extended Duration
Figure 1. Schematic diagram of the expression vectors
containing the S or L protein coding sequence from HBV. The
expected protein products are indicated as thick gray lines below the
respective coding sequences. b= b-lactamase secretion signal se-
quence.
doi:10.1371/journal.pone.0101715.g001
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Substrate (Fisher Scientific, Schwerte, Germany) and visualized by
a CCD camera.
Secreted HBsAg was analyzed in cell culture supernatants 72 h
after transfection by ELISA MonolisaTM HBsAg ULTRA (Bio-
Rad, Redmond, USA) according to the manufacturer’s instruc-
tions and applying recombinant HBsAg (ProSpec-Tany Techno-
gene, East Brunswick, USA) as quantification standard.
Immunogenicity study in mice
Female BALB/c mice, 12 weeks of age at the first administra-
tion and weighing 17.8–21.4 g, were supplied by Charles River
Table 1. Study design - immunization of pigs with MIDGE-Th1 DNA vaccine candidates and protein vaccine Engerix-B.
Test item Group DNA or protein dose (mg) Injection volume (ml) Route No. of pigs
Negative Control (SAINT-18) Ctrl. 0 200 i.d. 3
MIDGE-S-Th1/SAINT-18 low S 83 50 i.d. 5
MIDGE-S-Th1/SAINT-18 mid S 167 100 i.d. 4
MIDGE-S-Th1/SAINT-18 high S 333 200 i.d. 5
MIDGE-L-Th1/SAINT-18 high L 333 200 i.d. 5
Engerix-B (human dose) Engerix-B 20 1000 i.m. 4
doi:10.1371/journal.pone.0101715.t001
Figure 2. Expression of HBV antigens in CHO-K1 cells. Cells were transfected with expression vectors encoding the S or the L protein or eGFP
as control (Ctrl.). Expression in cell lysates was detected by Western Blot using polyclonal S protein-specific antibody (A) or PreS1-specific mouse
serum (B). rec. HBsAg: recombinant S protein of HBsAg. (C) Cells were transfected with the indicated amounts of single expression vectors or mixtures
thereof. S protein expression was analyzed by ELISA in supernatants of cells 72 h after transfection.
doi:10.1371/journal.pone.0101715.g002
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Laboratories (Sulzfeld, Germany). All mice were acclimatized for 7
days before immunization. Mice (n = 6 per group, allocated by
means of a computer randomization program) were immunized
intradermally (i.d.) into the dorsal skin of the tail base with
formulations of 10 mg MIDGE-Th1 vectors (c = 2 mg/ml) with
1 ml of 7.5 mM SAINT-18 in water (at the optimal w/w ratio
MIDGE-Th1/SAINT-18 of 1:0.5 [23]) on test days 1 and 21. As
negative control, mice received SAINT-18 only. On test day 35,
blood was collected from the retrobulbar venous plexus under ether
anaesthesia and animals were sacrificed by cutting the aorta
abdominalis. Sera were obtained and HBsAg specific IgG1 and
IgG2a antibodies determined as previously described [20]. The
detection limit of the ELISA was 39 pg/ml for IgG1 and IgG2a.
For determination of PreS1-specific antibodies in sera of mice,
ELISA plates were coated with 1 ng/ml PreS1 antigen (Abzymo
biosciences, Beijing, China). As detection antibody, HRP-conju-
gated goat anti-mouse IgG (115-035-003, Jackson ImmunoRe-
search, West Grove, USA) at 1:15,000 dilution was applied. HRP
activity was detected using Substrate Reagent Pack (DY999, R&D
Systems, Minneapolis, USA). The optical density (OD) was
measured at 450 and 595 nm. The titers were determined as the
highest serum dilution yielding an OD450–595 more than twice as
high than the mean OD450–595 of the negative control group.
Determination of PreS2-specific antibodies was performed as
described for PreS1 except that ELISA plates were coated with
1 ng/ml of an equimass mixture of three peptides spanning the
PreS2 amino acid sequence (amino acid 4–21, amino acid 22–38,
amino acid 39–55; Proteogenix).
Immunogenicity study in pigs
Male outbred Landrace pigs, 9–10 weeks of age at the first
administration and weighing 16.1 kg – 22.9 kg were supplied by
BHZP GmbH (Dahlenburg-Ellringen, Germany). All pigs were
acclimatized for 2 weeks before immunization and allocated to six
groups (Table 1) by means of a computer randomization program.
Pigs were immunized i.d. into the dorsal area of the left and right
ear (alternating between immunizations) with formulations of
MIDGE-Th1 vectors with SAINT-18 at the optimal w/w ratio
MIDGE-Th1/SAINT-18 of 1:0.5 [23] (Table 1). For comparison,
pigs received SAINT-18 only at the same injection volume as the
high dose groups of the MIDGE-Th1/SAINT-18 vaccine
candidates. As positive control, pigs were immunized intramuscu-
larly (i.m.) into the left and right side (alternating between
immunizations) of the neck with an adult-human dose of Engerix-
B (GlaxoSmithKline Biologicals, Rixensart, Belgium). Pigs were
primed on test day 1 and boosted on test days 29 and 57. After the
last blood sampling, the animals were returned to LPT’s animal
stock as a source of plasma or serum samples.
Measurement of antibody responses in pigs
At various time points, blood was collected from the vena cava
superior of each animal into serum separator tubes (Sarstedt,
Nu¨rnbrecht, Germany) and allowed to clot for approximately
0.5 h. Afterwards, the samples were centrifuged at 4,2006 g for
5 min at room temperature. Total S protein-specific antibodies
were determined using the Enzygnost Anti-HBs II kit according to
the manufacturer’s instructions.
The HBsAg-coated ELISA plates of the Enzygnost Anti-HBs II
kit were used to measure S protein-specific IgG1 and IgG2
antibodies. Mouse anti-porcine IgG1 and mouse anti-porcine
IgG2 (MA1-80545 and MA1-80546, Thermo Scientific, Rockford,
USA), diluted 1:250 and 1:100, respectively, served as secondary
antibodies, and HRP-conjugated goat anti-mouse IgG (115-135-
146, Jackson ImmunoResearch), diluted 1:30,000, was used for
detection. The level of S protein-specific IgG1 and IgG2 was
determined as RLU/ml based on a standard derived from pooled
sera of animals positive for total S protein-specific antibodies
(measured as described above). The response was set to
8192 RLU/ml. Calibration standards were prepared by diluting
the pooled positive porcine serum. The lowest calibration standard
Figure 3. HBV antigen-specific humoral immune responses in
mice after two intradermal immunizations with SAINT-18
(Ctrl.), 10 mg MIDGE-Th1 vectors encoding the S or the L
protein or an equimass mixture of these vectors (Mix). MIDGE-
Th1 vectors were formulated with SAINT-18. Mice were immunized on
day 1 and 21 and serum samples were analyzed by ELISA for S protein-
specific IgG1 (A) and IgG2a (B) and for PreS1-specific IgG (C) on day 35.
(A), (B): Each symbol represents an individual mouse serum sample. The
mean is shown for each group as horizontal line (n = 6). (C): PreS1-
specific IgG were measured at 1:25, 1:125 and 1:625 dilution and OD450–
595 values expressed as mean and SD of six mice per group. Statistical
analysis: (A, B) ANOVA, not significant. (C) Dunnett, L/Ctrl. 1:25 dilution:
*p = 0.028; Tukey, L/S 1:25 dilution: *p = 0.043; other dilutions and
group comparisons were not significant.
doi:10.1371/journal.pone.0101715.g003
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(16 RLU/ml for IgG1; 8 RLU/ml for IgG2) was accepted as
lower limit of quantification.
PreS1-specific and PreS2-specific antibodies were determined as
described in 2.4, except that HRP-conjugated goat anti-pig IgG
(ab6915, Abcam) at 1:15,000 dilution served as detection
antibody. For every animal, the endpoint dilution titer was
expressed as the highest reciprocal dilution of test serum yielding
an OD450–595 more than twice as high than that obtained with the
same dilution of pre-immune serum. For graphical and statistical
purposes, samples tested negative were set to a titer of 10.
Measurement of cellular responses in pigs
On test days 43 and 71, blood was withdrawn from the vena cava
superior and collected into lithium-heparin-collection tubes (Sar-
stedt). The samples were subjected to a density centrifugation
using Histopaque (Sigma-Aldrich).
The obtained peripheral blood mononuclear cells (PBMC) were
suspended in medium (RPMI 1640, Invitrogen, Carlsbad, USA)
supplemented with 10% (v/v) FBS, 100 U/ml penicillin and
100 mg/ml streptomycin and 2 mM a-glutamine. The cells were
activated in vitro by addition of peptide pools (2 mg/ml for each
peptide). Peptide pools consisted of 15-mer peptides with 11-mer
overlaps covering the S, PreS1 and PreS2 amino acid sequence
(peptides&elephants, Potsdam, Germany). As positive and negative
control, PBMC were incubated with ConA (10 mg/ml) and with
medium only. The ELISpot was carried out in duplicates using
Porcine IFN-c ELISpot Kit (EL985, R&D) with an incubation
time of 18 hours. The ELISpot analysis was conducted using
ImmunoScan Entry (CTL Europe, Bonn, Germany). The number
of IFN-c-secreting cells per 16106 PBMC was expressed as the
difference between the number of spots in the stimulated wells and
the number of spots in the medium control wells.
Statistical analysis
Data were analysed with SPSS 15.0 (SPSS Inc., Chicago, USA).
Normal distribution of data was confirmed using Kolmogorov-
Smirnoff test prior to analyzing differences between the means of
several experimental groups using one-way ANOVA and subse-
quent post-hoc analysis (two-sided Dunett’s test for multiple
comparisons of treatment groups with negative control group;
Tukey’s test for multiple pairwise comparisons of treatment
groups). The significance level a was set to 5%.
Results
Construction of MIDGE-Th1 vectors and expression of
HBV antigens in vitro
Conventional Hepatitis B vaccines are based on the S protein of
HBsAg, so for direct comparison we generated an expression
vector encoding the same antigen (S in Figure 1). Aiming to
develop a hepatitis B vaccine inducing a broader set of antibodies
than conventional protein vaccines and thereby increasing efficacy
in weak or non-responders, we encoded the L protein in our
second vector and thus included the DNA sequences of the PreS1
Figure 4. Kinetics of HBV antigen-specific humoral immune responses in pigs. Pigs were immunized with SAINT-18 (Ctrl.), a low, mid or
high dose of SAINT-18-formulated MIDGE-Th1 vectors encoding the S protein (low S, mid S, high S), a high dose of SAINT-18-formulated MIDGE-Th1
vectors encoding the L protein (high L) or a human dose of Engerix-B on days 1, 29 and 57 (Q). Serum samples were collected on various test days
and analyzed by ELISA for total S protein-specific antibodies (A), PreS1-specific IgG (B), S protein-specific IgG1 (C) and IgG2 (D). Data points represent
mean values for all animals in each group (n = 3–5). For graphical purposes, samples without a PreS1-titer were set to 10 in (B). Statistical analysis is
presented in Tables S1–S4.
doi:10.1371/journal.pone.0101715.g004
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and PreS2 domains. Keeping the viral amino acid sequences, the
DNA sequences of the S and the L protein were codon-optimized
for enhanced expression in humans. Internal transcriptional and
translational start sites were removed from the L protein coding
sequence to express predominantly the full-length L protein, and
the b-lactamase signal sequence was added to mediate secretion
[22] (L in Figure1). The optimized synthetic antigen coding
sequences were each placed under control of a strong viral PCMV
promoter.
Subsequently, CHO-K1 cells were transfected with the vectors
and HBsAg expression was confirmed by Western blot analysis
with an S protein-specific primary antibody (Figure 2A). In cells
transfected with the S protein-encoding vector, the non-glycosy-
lated form of the S protein was detected (molecular weight:
,24 kDa [3]). Furthermore, dimers of the S protein at higher
molecular weight were visible that were also detected in the
positive control (recombinant S protein of HBsAg). In cells
transfected with the L protein-encoding vector, the L protein was
detected (bands between 35 and 55 kDa for monomers and
between 100 and 130 kDa for multimers) due to its S protein
domain. Expression of the full length L protein was confirmed with
polyclonal mouse serum specific for the PreS1 domain (Figure 2B).
Cells transfected with the L protein-encoding vector expressed the
non-glycosylated and glycosylated forms of the L protein
(molecular weight: 39 and 42 kDa [3]). Additionally, multimers
of the L protein were detected at higher molecular weight. A lower
molecular weight band of ,32 kDa was probably due to
unspecific binding of the polyclonal mouse serum.
Next, we evaluated secretion of antigens into the supernatant of
transfected cells. We hypothesized that a mixture of MIDGE-Th1
vectors encoding S and L protein was a possible scenario for a
novel HBV vaccine to induce strong anti-S antibodies and strong
anti-PreS1 and anti-PreS2 antibodies. Thus, CHO-K1 cells were
transfected with individual vectors or with an equimass mixture
Figure 5. HBV antigen-specific humoral immune responses in pigs after three immunizations. Pigs were immunized with MIDGE-Th1
DNA vaccine candidates and Engerix-B on days 1, 29 and 57 (see legend Figure 4) and serum samples were analyzed by ELISA for total S protein-
specific antibodies (A), PreS1-specific IgG (B), S protein-specific IgG1 (C) and IgG2 (D) on day 71. Each symbol represents an individual pig serum
sample. The mean is shown for each group as horizontal line (n = 3–5). For graphical and statistical purposes, samples without a titer were set to 10 in
graph (B). Statistical analysis: (A) Dunnett, high S/Ctrl. *p = 0.011, Engerix-B/Ctrl. *p = 0.015; Tukey, Engerix-B/high L *p= 0.019, high S/high L
*p= 0.012. (B) Dunnett, high L/Ctrl. ***p = 0.00002, Tukey, high L/low S ***p = 0.00002, high L/mid S ***p = 0.00007, high L/high S ***p = 0.00006, high
L/Engerix-B ***p = 0.00004 (C) Dunnett, Engerix-B/Ctrl. ***p= 0.00002; Tukey, Engerix-B/low S **p = 0.002, Engerix-B/mid S ***p = 0.0002, Engerix-B/
high S **p = 0.001. Engerix-B/high L ***p= 0.00003. (D) Dunnett, high S/Ctrl. **p = 0.006; Tukey, Engerix-B/high S *p= 0.024, high L/high S **p = 0.007,
mid S/high S day 71: *p = 0.026. Other group comparisons were not significant.
doi:10.1371/journal.pone.0101715.g005
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and supernatants were analyzed for the presence of secreted
surface antigens by S protein-specific ELISA. Surprisingly, cells
transfected with S protein-encoding vector secreted ,250–300-
fold more HBsAg than cells transfected with the same DNA
amount of L protein-encoding vector (Figure 2C). Cells transfected
with a mixture of each 10 mg S and 10 mg L protein-encoding
vector secreted ,50% less HBsAg in comparison to cells
transfected with 10 mg S protein-encoding vector. Obviously, co-
expression of S and L protein impaired HBsAg secretion.
Immunogenicity study in mice
We next explored how the level of in vitro protein expression and
secretion translates into the generation of anti-S humoral immune
responses in vivo and whether PreS1- and PreS2-specific antibodies
are induced. BALB/c mice were immunized with 10 mg MIDGE-
Th1 vectors encoding either the S or the L protein or with 10 mg
of an equimass mixture of these vectors on days 1 and 21. The
DNA was formulated with SAINT-18 and administered i.d. to
induce strong immune responses [20]. The concentration of S
protein-specific antibodies was determined by ELISA in sera
collected 14 days post boost immunization. S protein-encoding
vectors elicited 6-fold and 4-fold higher S-specific IgG1 levels than
L protein-encoding vectors and the equimass mixture, respectively
(Figure 3A). S-specific IgG2a levels were also 6-fold and 5-fold
higher in mice immunized with S protein-encoding vectors
compared to L protein-encoding vectors and the vector mixture,
respectively (Figure 3B).
Mice vaccinated with MIDGE-L-Th1 developed a significant
anti-PreS1 immune response (Figure 3C), albeit with a rather low
antibody titer (1:125). The vector mixture induced no measurable
anti-PreS1 response (Figure 3C). PreS2-specific antibodies were
not detected in any group (data not shown). In summary, we did
not observe a benefit of immunization with the vector mixture
over the single MIDGE-Th1 vectors encoding either the S or the L
protein in mice. Therefore, we proceeded with the single vectors
and examined immunogenicity and efficacy of these vaccine
candidates in a large animal model.
Immune responses of pigs to S and L protein of HBsAg
To establish the proof of concept of the SAINT-18-formulated
MIDGE-Th1 DNA vaccine candidates, we compared their
immunogenicity and protective efficacy with a full human dose
of the licensed, aluminium-hydroxide-adjuvanted protein vaccine
Engerix-B in pigs. The total S protein-specific antibody level in
serum is an established surrogate parameter for protection of
prophylactic vaccines against HBV and a level of 10 mIU/ml is
considered to be protective against HBV infection in humans [5].
We immunized 9–10 weeks old male pigs with SAINT-18-
formulated MIDGE-Th1 vectors or Engerix-B on days 1, 29 and
57 (Table 1). MIDGE-Th1 vectors encoding the S protein were
tested in a low, intermediate (mid) and high dose to examine the
influence of the dose on the strength of immune response. In
consequence of its lower immunogenicity in mice, pigs received
only the highest possible dose of the L protein-encoding vector. At
various time points blood samples were collected and anti-S (total
Ig, IgG1 and IgG2), anti-PreS1 (IgG) and anti-PreS2 (IgG)
antibodies determined in sera. Figure 4 shows the kinetics of the
humoral immune response and Figure 5 presents individual
animal data after three immunizations on day 71. The results of
the statistical data analysis are listed in Tables S1–S4.
Considerable levels of total S protein-specific antibodies were
detected in the three MIDGE-S-Th1/SAINT-18 dose groups
(Figures 4A and 5A). Indeed, all animals seroconverted (levels $
10 mIU/ml) already 14 days after a single immunization (day 15,
individual animal data not shown). With every injection, the
antibody response was boosted. The strongest response was
observed at the highest dose level two weeks after the third
immunization (day 71). At any time point, differences among the
MIDGE-S-Th1/SAINT-18 dose groups were not significant
(Table S1).
Engerix-B elicited a similar level of total S protein-specific
antibodies as MIDGE-Th1 vectors encoding the S protein.
Differences were only significant for the low and mid dose on
day 29 (Table S1) and disappeared on day 71 (Figure 5A).
Comparing the S protein-specific IgG1 and IgG2 response, a
striking difference between immunization with S protein-encoding
MIDGE-Th1 vectors and Engerix-B became evident (Figure 4C
and D; Figure 5C and D): Engerix-B induced approximately
three- to eight-fold more IgG1 and 10-fold less IgG2 than
MIDGE-S-Th1/SAINT-18. These differences were significant at
various test days (Tables S3 and S4).
L protein-encoding vectors induced 1,000-fold lower levels of
total S protein-specific antibodies than S protein-encoding vectors
(Figure 4A) but still, four out of five animals responded (levels $
10 mIU/ml) two weeks after the third immunization (Figure 5A).
Furthermore, this vaccine candidate induced significant anti-
PreS1 titers in comparison to the negative control group
(Figure 4B, Figure 5B, Table S2). Three out of five animals were
Figure 6. HBV antigen-specific cellular immune responses in pigs after three immunizations. Pigs were immunized with MIDGE-Th1 DNA
vaccine candidates and Engerix-B (see legend Figure 4) and PBMC were obtained from blood collected on day 71. The cells were activated in vitro by
addition of S protein peptide pool (A), PreS1 peptide pool (B) or PreS2 peptide pool (C). The number of IFN-c-spot forming cells (SFC) per 106 PBMC
was expressed as the difference between the number of spots in the stimulated wells and the number of spots in the medium control wells. Each
data point represents an individual sample and group means are indicated as horizontal lines. Statistical analysis: (A, B, C) ANOVA, not significant.
doi:10.1371/journal.pone.0101715.g006
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already positive at day 29 (28 days after a single immunization,
individual animal data not shown). The titers increased with each
subsequent immunization (Figure 4B) and all animals were positive
two weeks after the third immunization (Figure 5B). Unexpectedly,
some animals immunized with the S protein-encoding vector also
developed anti-PreS1 titers. PreS2-specific antibodies were not
detected in any treatment group (data not shown).
Figure 7. Duration of HBV antigen-specific humoral immune responses in individual animals. Pigs were immunized with MIDGE-Th1
DNA vaccine candidates and Engerix-B (see legend Figure 4) and serum samples were collected and analyzed by ELISA for total S protein-specific
antibodies (A), S protein-specific IgG1 (C) and IgG2 (C) on various test days up to 6 months after the third immunization. The animal number is shown
in the legend of the graph.
doi:10.1371/journal.pone.0101715.g007
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To assess cellular immune responses, PBMC were analyzed for
antigen-specific IFN-c-secreting cells by ELISPOT two weeks
after the second (data not shown) and third immunization
(Figure 6). Pigs immunized with the S protein-encoding vector at
different doses developed clearly more S protein-specific IFN-c-
secreting PBMC than pigs of the negative control group
(Figure 6A). Here we found a slight, albeit non-significant, effect
of the DNA dose. The highest dose of MIDGE-S-Th1/SAINT-18
induced the same level of IFN-c-secreting PBMC as Engerix-B
whereas MIDGE-L-Th1/SAINT-18 induced only few S-specific
IFN-c-secreting PBMC.
Upon stimulation with PreS1 and PreS2 peptide pools, we
observed only very low numbers of IFN-c-secreting cells (Figure 6B
and C). Pigs immunized with L protein-encoding vectors exhibited
more IFN-c-secreting PBMC than pigs of the negative control
group. However, comparable numbers of IFN-c-secreting PBMC
were detected in animals immunized with S protein-encoding
vectors at the same dose. Thus, the detected cellular responses
were not considered to be specific for PreS1 and PreS2.
Duration of humoral immune response in pigs
To assess whether formulated MIDGE-Th1 DNA vaccines
conferred long-lasting antibody responses, we monitored two
animals each per treatment group low and high dose MIDGE-S-
Th1/SAINT-18 and Engerix-B for 6 months after the third
immunization. Animals were selected for further monitoring based
on total S protein-specific antibodies on day 71 (Table S5).
From day 71 to day 253, a ,2.5-fold reduction of total anti-S
antibody levels was observed in animals (No. 18 and 20)
immunized with S protein-encoding vectors at high dose. The
contraction was more pronounced in Engerix-B-immunized
animals with 10-fold (animal 32) respectively 24-fold (animal 35)
reduced levels (Figure 7A). Animal 7 of the low dose MIDGE-S-
Th1/SAINT-18 group showed a 2-fold increase of total anti-S
antibody levels, whereas the other animal (No. 9) exhibited a 10-
fold reduction in the same period. All six animals still had
protective antibody levels at the end of the study regardless of the
vaccine they had received.
The S protein-specific IgG1 levels decreased ,10-fold in
animals immunized with S protein-encoding vectors from day 71
to day 253, except for animal 7 for which levels had dropped to
background already by day 162 (Figure 7B). Again, levels in
animals immunized with Engerix-B decreased strongly (,25-fold
from day 71 to day 253).
From day 71 to day 162 the S protein-specific IgG2 levels
decreased ,7–10-fold in all animals. Thereafter, S protein-specific
IgG2 levels of animals immunized with S protein-encoding vectors
remained constant until day 253, whereas the levels in animals
immunized with Engerix-B further decreased over time
(Figure 7C).
Discussion
In the work reported here, we aimed to develop an improved
hepatitis B vaccine and for this purpose, used SAINT-18-
formulated MIDGE-Th1 vectors to express the S or the L protein
of HBsAg. HBV DNA vaccines generally induce stronger humoral
immune responses when epitopes are presented on secreted
subviral particles [24]. The expected strong secretion of the S
protein was confirmed in CHO-K1 cells transfected with the S
protein-encoding vector. L protein secretion was intended to be
enhanced by insertion of the b-lactamase secretion signal sequence
as previously reported by others [22,24], but our cell culture assays
showed that the L protein was, nevertheless, mainly retained
intracellularly. Co-transfection of CHO-K1 cells with S and L
protein-encoding vectors hampered HBsAg secretion.
Surprisingly, the intracellular retention of the L protein was not
reflected in a correspondingly low immunogenicity of the L
protein-encoding vector in mice. In fact, the difference in S-
specific antibody responses induced by S and L protein-encoding
MIDGE-Th1 vectors was less pronounced than anticipated from
the,250–300-fold difference in antigen secretion observed in vitro.
This suggests that low amounts of secreted antigen are sufficient to
induce antibodies in mice and that excess amounts of S protein
expressed from MIDGE-S-Th1 do not necessarily further increase
antibody levels. It is also conceivable that intracellularly retained L
protein contributed to the induction of humoral immune responses
as shown before for DNA immunization with other L protein
expression vectors [25,26]. In contrast to a distinctive humoral
immune response to PreS1, no PreS2-specific antibodies were
detected after immunization of mice with the L protein-encoding
vector. This is consistent with other studies describing lower
overall anti-PreS2 antibody titers in comparison to anti-PreS1
antibody titers after immunization with DNA vectors encoding the
L protein [24] or with a PreS1-, PreS2- and S-containing protein
vaccine [27]. When we immunized mice with a mixture of the two
DNA vectors encoding the S and the L protein, we did not observe
an immunological benefit over immunization with the individual
vectors. We therefore discarded the mixture as potential vaccine
candidate and proceeded with individual, SAINT-18-formulated
MIDGE-Th1 vectors expressing either S or L protein as vaccine
candidates. To predict efficacy of these vaccine candidates in
humans, we evaluated their immunogenicity in a suitable large
animal model and compared them to the protein vaccine Engerix-
B. The pig model is considered appropriate as it allows for
comparison of vaccines at full human doses. Considering that
intradermal administration is the intended clinical route of our
DNA vaccine candidates, the morphological similarity of porcine
to human skin [28] is relevant. In addition, pigs have been
reported to develop immune responses to HBsAg [29,30,31].
Delivery of naked HBsAg-encoding DNA vectors by needle and
syringe has been reported to induce only weak immune responses
in contrast to delivery by electroporation, emphasizing the need
for a delivery system to enhance the efficacy of DNA vaccination.
Based on our previous studies in mice [20] we hypothesized that
formulation with SAINT-18 is an efficient delivery method for
MIDGE-Th1 vectors in pigs as well.
Indeed, both vaccine candidates generated S protein-specific
antibody levels in pigs that would be considered protective in
humans. A single immunization with S protein-encoding vectors
achieved 100% seroconversion at all tested DNA doses. In
contrast, three immunizations with L protein-encoding vectors at
high dose induced only 80% seroconversion at ,1000-fold lower
levels. The effect of low antigen secretion from L protein-encoding
vectors on the induction of S protein-specific antibodies was
obviously more pronounced in pigs than in mice. The lower
immunogenicity of L protein-encoding vectors was also reflected
by the weak cellular immune response detected in pigs. Only low
amounts of S-specific and no PreS1- and PreS2-specific IFN-c-
secreting PBMC were detected. In mice, strong S-specific [32,33]
and negligible PreS1/PreS2-specific [33] cellular responses have
been described after immunization with DNA vaccines expressing
non-secreted L proteins. The comparably high DNA doses applied
in those studies (15 mg [33] or 100 mg DNA [32] for a ,20 g
mouse) as opposed to 333 mg DNA for a ,20 kg pig used in our
study might explain the different level of S-specific cellular
immune responses.
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Comparing the immunogenicity of S protein-encoding vectors
to Engerix B, we observed a similar level of S protein-specific
antibodies and comparable cellular immune responses. Only few
side-by-side studies measuring the efficacy of DNA vaccines in
comparison to licensed protein vaccines have been performed so
far, especially not in relevant large animal models. Babiuk et al.
showed 100% seroconversion after two immunizations of pigs with
1000 mg HBsAg-encoding plasmid delivered by electroporation
[29] and the same seroconversion rate was postulated for two
immunizations with Engerix-B [30]. In chimpanzees, a high dose
of plasmid DNA (2 mg) encoding for PreS2 and S protein induced
the same level of antibodies as a commercial protein subunit
vaccine [34]. In comparison, our study showed that formulation
with SAINT-18 is an effective delivery method for DNA vaccines,
notably MIDGE-Th1 vectors, since a DNA dose as low as 83 mg
was effective in pigs.
For mice, it is established that immunization with DNA and
aluminum-hydroxide-adjuvanted protein vaccines against HBV
elicits a Th-type 1 (Th1) and Th2 type biased immune response,
respectively [35,36]. In our pig study, we also observed that
Engerix B induced high amounts of IgG1 antibodies whereas
MIDGE-Th1 vectors induced more IgG2 antibodies. Though the
function of Ig isotypes in pigs has not been as extensively
described, Th2 cytokines have been shown to increase the
IgG1:IgG2 ratio [37], indicating that Ig isotype production in
pigs may follow the Th1/Th2 paradigm suggested for mice [38].
However, the apparent difference in the type of humoral immune
response was not reflected by the cellular immune responses since
the S protein-encoding vector and Engerix-B induced the same
level of S protein-specific IFN-c-secreting PBMC.
The PreS1-specific antibody titers detected in some animals
immunized with S protein-encoding vectors, though at a low level,
was unexpected. These antibodies might be cross-reactive with low
specificity for the PreS1 protein, although sequence alignments
revealed no similarity between the PreS1 and S protein amino acid
sequence. In this context it is puzzling that the S protein-specific
antibodies induced by Engerix-B were not cross-reactive. S protein
expressed from DNA in immunized animals differs from
recombinant yeast-derived S protein (e.g. folding, glycosylation)
and antigen presentation after DNA and protein immunization
might deviate as well which potentially influences the development
of cross-reactive antibodies.
In humans, antibody levels wane over time after vaccination
with recombinant HBsAg protein vaccines [39]. Accordingly, we
have observed a decline in antibody levels within 6 months after
the third immunization of pigs. Though the low number of
animals allows no definitive conclusion, the decline seemed less
pronounced in pigs immunized with S protein-encoding MIDGE-
Th1 vectors compared to pigs immunized with Engerix-B.
Prolonged presence of the MIDGE-Th1 vector in skin and
draining lymph nodes [23] resulting in prolonged antigen
expression and immune stimulation may account for this effect.
Another possible explanation is that the DNA vaccine induced
more long-lived antibody-secreting plasma cells [40] maintaining
specific antibody levels in the absence of antigen.
From our studies in mice and pigs we conclude that the SAINT-
18-formulated MIDGE-Th1 vector encoding the S protein of
HBsAg is the most promising vaccine candidate at present.
Although immunogenicity in humans remains to be determined,
our data indicate that the generation of total S-specific antibodies,
the hallmark for licensing of HBV vaccines, can approach that of
conventional vaccines after immunization with this vaccine
candidate. Although the L protein-encoding vector elicited high
PreS1-specific antibody titers in pigs, the level of S-specific
antibodies does not suggest that this vaccine candidate can confer
protection in humans. Thus, further optimization of the L protein
antigen sequence, e.g. allowing for efficient secretion of the L
protein [36], would be required prior to clinical testing.
Taken together, we established efficacy of our SAINT-18-
formulated MIDGE-Th1 DNA vaccine for prophylaxis of HBV
infection in a large animal model. With this relevant proof of
concept, the application of SAINT-18 formulated MIDGE-Th1
vectors can be expanded to the development of other prophylactic
vaccines with an antibody-based mode of protection against a
broad range of pathogens.
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